Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-06-01-Speech-4-152"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2006-06-01"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20060601.27.4-152"2
lpv:hasSubsequent	lp_eu:2006-06-01-Speech-4-1532
lpv:speaker	lp:Gérard Deprez2
lpv:spokenAs	member; ALDE (2004-07-20--2008-02-10)3 substitute; Delegation for relations with Mercosur (2004-09-15--2007-03-13)3 substitute; LIBE (2004-07-22--2007-01-14)3 unknown; Mouvement Réformateur (2004-07-20--2009-07-13)3 member; Delegation to the EU-Turkey Joint Parliamentary Committee (2004-09-15--2007-03-14)3 member; BUDG (2004-07-21--2007-01-14)3
lpv:translated text	"Thanks to the adoption of this recommendation concerning paediatric medicines and the agreement between Parliament and the Council, henceforth children will be able to benefit from medicines appropriate for their specific metabolism rather than having to be prescribed weak doses of medicines intended for adults. I believe that here we have tried to combine all the conditions necessary for the intelligent introduction, in Europe, of pharmaceutical forms specifically for children: provisions concerning support for innovation and research incentives for laboratories (notably with six months’ additional protection for the protection certificate), the establishment of an inventory of therapeutic needs specifically in paediatrics, the requirement to develop a paediatric form for new medicines, measures intended to ensure that medicinal products, once developed, are distributed throughout the Member States, or else special derogations to ensure that the development of paediatric products nonetheless does not hamper the development of medicinal products intended for adults. We have here a concrete example of the added value of a Community regulation: a single Member State would never have had the means on its own to promote such a policy in relation to specific medicinal products."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph